Jump to content

Taisho Pharmaceutical

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Johnpacklambert (talk | contribs) at 23:20, 26 September 2015 (added Category:1912 establishments in Japan using HotCat). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Taisho Pharmaceutical Co., Ltd. (大正製薬株式会社, Taishō Seiyaku Kabushiki-gaisha) (TYO: 4535) is a Japanese pharmaceutical company based in Tokyo.

History

Taisho was established in 1912 to produce over-the-counter drugs. The company moved into prescription drug R&D in 1955.

Products

The company's principal line of business is over-the-counter (OTC) medicines, where it markets the brands Lipovitan-D, Pabron, Colac, and others. In prescription pharmaceuticals, the company's most successful product to date has been the macrolide antibiotic clarithromycin. The company's branded version of the drug, Clarith, was launched in Japan in 1991. For clarithromycin distribution outside Japan Taisho licensed Clarithromycin To Abbott Laboratories.

Ownership

Taisho Pharmaceutical's stock is traded on the Tokyo Stock Exchange where its security code is 4535. Principal owners of the firm are the Uehara family.


Stub icon

This article about a Japanese corporation- or company-related topic is a stub. You can help Wikipedia by expanding it.

Stub icon

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Taisho_Pharmaceutical&oldid=682919922"